Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets

This article was originally published in The Pink Sheet Daily

Executive Summary

For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.
Advertisement

Related Content

Private Grünenthal Aims For Leadership In Pain
Private Grünenthal Aims For Leadership In Pain
UCB May Be Stagnating Today, But Promises There Will Be Growth Tomorrow
GSK’s Strategy in Emerging Markets: Scale, Diversification and Access
GSK Sees Emerging Market Opportunity In Thinking Locally, Developing Locally
UCB Inks Buyback-Option Deal With Wilex For Oncology Lineup
Cimzia Rheumatoid Arthritis Approval Held Up By Safety Request
UCB’s Neupro Manufacturing Problems Hold Up Approval For Advanced Parkinson’s Disease
UCB Trims Down With SHAPE Program
UCB Trims Down With SHAPE Program

Topics

Advertisement
UsernamePublicRestriction

Register

PS068507

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel